BMRN - Latest News

BioMarin Pharmaceutical Inc. (BMRN), operates in Healthcare / Biotechnology, trades on NASDAQ.

Market capitalization stands near $10.67B. Trailing twelve-month P/E ratio is 145.81. Beta to the broader market is 0.22.

The article list below shows the most recent BMRN headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.

Recent BMRN Headlines

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock

zacks.com - Oct 13, 2026

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Financial Review: Relay Therapeutics (NASDAQ:RLAY) & BioMarin Pharmaceutical (NASDAQ:BMRN)

defenseworld.net - Oct 12, 2026

Relay Therapeutics (NASDAQ: RLAY - Get Free Report) and BioMarin Pharmaceutical (NASDAQ: BMRN - Get Free Report) are both healthcare companies, but wh

BioMarin Presents New Data Advancing Understanding of Achondroplasia and Hypochondroplasia Treatment at the American Society for Bone and Mineral Research Annual Meeting

prnewswire.com - Oct 9, 2026

New analysis showcases impact of VOXZOGO® (vosoritide) in foramen magnum and craniocervical junction growth in children with achondroplasia, including

FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing

zacks.com - Oct 7, 2026

BBIO wins FDA priority review for infigratinib, potentially making it the first approved oral therapy for achondroplasia.

BioMarin Appoints Cara Bauer as Chief People Officer

prnewswire.com - Oct 5, 2026

Ms. Bauer Brings More Than 25 Years of Experience in Human Resources, Across Biotechnology and Technology Industries Appointment Effective Oct.

How News Affects BMRN Options Pricing

Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track BMRN's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.

Frequently asked BMRN news questions

What is the latest BMRN news headline?

The most recent BMRN headline (Oct 13, 2026) is "Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.

How fresh is the BMRN news on this page?

News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.

What BMRN news moves options pricing?

Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.

How can I track unusual BMRN options activity related to news?

Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.